New chemo cocktail aims to shrink pancreatic tumors

NCT ID NCT07076212

Recruiting now Disease control Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two chemotherapy regimens for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. One group gets NALIRIFOX (a mix of four drugs) every two weeks, while the other gets a modified version of gemcitabine, nab-paclitaxel, and cisplatin every four weeks. The goal is to see which combination shrinks more tumors. The trial is recruiting 52 adults who have not had prior treatment for their cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy combination (liposomal irinotecan, oxaliplatin, 5-fluorouracil, leucovorin vs gemcitabine, nab-paclitaxel, cisplatin)
What this could lead to: If NALIRIFOX works better than the other combo, it could become a new standard treatment for advanced pancreatic cancer, potentially shrinking more tumors and extending life.
What could go wrong: This is a small, early Phase 2 trial with only 52 people, so results may not apply to everyone. Chemotherapy has serious side effects, and the new combo might not be more effective than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA METASTATIC PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

Hollings Cancer Center at Medical University of South Carolina
RECRUITING

Charleston, South Carolina, 29425, United States
Medical University of South Carolina Hollings Cancer Center
RECRUITING

Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.